Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer

24 Aug 2020

Abstract excerpt

Multifunctional platinum IV anticancer prodrugs have the potential to enrich the anticancer properties and overcome the clinical problems of drug resistance and side effects of platinum II anticancer agents. Herein, we develop dual and triple action platinum IV complexes with targeted and biological active functionalities. One complex ( PFL ) that consists of cisplatin, tegafur, and lonidamine exhibits strong...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to Metal complexes synthesis and properties

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32838518
DOI: 10.1021/acs.inorgchem.0c01736

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast CancerPMID 32838518Read ↗

DNA-Unresponsive Platinum(II) Complex Induces ERS-Mediated Mitophagy in Cancer CellsSemantic proximity Read ↗

A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin ResistanceSemantic proximity Read ↗

A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin ResistanceSemantic proximity Read ↗

A New Strategy to Fight Metallodrug Resistance: Mitochondria‐Relevant Treatment through Mitophagy to Inhibit Metabolic Adaptations of Cancer CellsSemantic proximity Read ↗

Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biologySemantic proximity Read ↗

Triple action Pt( iv ) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistanceSemantic proximity Read ↗

The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor AgentsSemantic proximity Read ↗

Platinum iodido drugs show potential anti-tumor activity, affecting cancer cell metabolism and inducing ROS and senescence in gastrointestinal cancer cellsSemantic proximity Read ↗

Cellular Discrepancy of Platinum Complexes in Interfering with Mitochondrial DNASemantic proximity Read ↗

Fresh Platinum Complexes with Promising Antitumor ActivitySemantic proximity Read ↗

Platinum Complexes as Anticancer AgentsSemantic proximity Read ↗

Red Blood Cell-derived Extracellular Vesicles enable Cisplatin and Cetuximab combined Therapy against Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.